Bull case
Why this leftover might be a real product question.
Mutation-agnostic restoration without gene or mRNA delivery. For genotypes that make no CFTR protein, ionophore anion transport is a different job than adding another inhaled CFTR mRNA.
Pursue diligence · N1 · Mutation-agnostic CFTR restoration
H2 · CFTR-independent airway anion transport
Opportunity Score: 72/100 · Evidence: Moderate
Worth a closer look — not a mandate to form a company This card inherits the parent leftover’s score. It is not a second ranking.
If N1 restoration is crowded, the differentiated bet is CFTR-independent anion transport.
Not medical advice, not a recommendation to buy or sell any security, and not a claim that any opportunity should be funded.
HYPOTHESIS
A score or thesis. Always shown with evidence and a way to kill it.
Nucleic-acid restoration is crowded; a bypass mechanism is the differentiated N1 bet.
FACT
A published number with a source and a date. You can check it.
After Alyftrek, CFF estimates ~92% eligible for at least one modulator. 2,434 people were ineligible by age or genotype; 1,226 ineligible adolescents/adults had Registry data. There is no approved mutation-agnostic CFTR restoration.
ANALYSIS
A filter or count this project computed, such as the reviewed CF map.
N1 has 13 industry investigational crowding units (gene therapy, mRNA, ASO). ABCI (amphotericin B cystetic for inhalation, Cystetic Medicines, NCT05802264) is the reviewed, industry, map-eligible Phase 1 ionophore that does not need CFTR protein. Complementary Sionna molecules count as one crowding unit elsewhere on the modulator map, not here.
INTERPRETATION
What we think the fact and analysis mean. Not a score yet.
A bypass mechanism is orthogonal to the crowded delivery race for nonsense and other no-protein genotypes. One early clinical program is a hedge, not a field. If nucleic-acid restoration works first, bypass becomes backup.
Bear case
Why it might already be solved, or never be a new company.
ABCI is early (healthy volunteers and people with CF). Chronic inhaled amphotericin-class ionophore safety, dosing, and airway irritation are the obvious failure modes. Company-formation here is close to a single-asset bet unless a second bypass mechanism appears.
Counterarguments
Reasons a skeptical reader would push back.
- Mutation-agnostic nucleic-acid delivery is the more direct causal fix if it works; bypass is a hedge, not a better biology story.
- Ionophore precedents outside CF do not automatically translate to lifelong inhaled use in damaged airways.
- One recruiting Phase 1 program is not evidence that the class is tractable at chronic doses.
What would have to be true
Assumptions the bet needs. If these fail, the thesis fails.
ABCI-class ionophores restore airway anion transport without CFTR protein; safety and chronic dosing work in people with CF including nonsense/rare genotypes; nucleic-acid programs do not fully cover the ineligible group first.
Kill the idea if
A pre-committed rule. If this happens, drop the thesis rather than talking yourself into it.
Kill if ABCI safety/tolerability fails or if a mutation-agnostic mRNA/gene therapy demonstrates clinically meaningful restoration in ineligible genotypes.
What to check next
- Track ABCI safety, sweat chloride or FEV1 signals, and whether chronic dosing is even attempted.
- Compare genotype coverage against the ineligible 12+ group (1,226 with Registry data), not the full 2,434 ineligible count.
- Do not count ABCI as whitespace if it stalls while remaining listed as recruiting.
Verdict
Pursue diligence as the differentiated N1 mechanism. It is not safer than nucleic-acid programs; it is less crowded.
This card inherits the parent need score. It is not a second ranking and not a funding recommendation.